The target compounds benzothiazole derivatives (8a-g) were synthesized starting from the norbornene. The antiproliferative activities of the compounds 6a-g and 8a-g were determined against C6 (rat brain tumor) and HeLa (human cervical carcinoma cells) cell lines using BrdU cell proliferation ELISA assay using 5-fluorouracil (5-FU) as standard. In both series, when compared with 5-FU (IC50=<5 µM for C6 and 16.33µM for HeLa), the most active compounds against C6 cells were 6a and 8g with IC50 values of 14.13 µM and 29.99 µM, respectively, while 6a, 6e, 6f and 8b were the most active compounds against HeLa cells with IC50 values of <5, <5, 19.33 and 1813 µM, respectively. Addition, to predict the physicochemical and AMDE properties of the tested compounds, SwissADME online web tool was used. The results showed that all compounds possess promising predicted physiochemical and pharmacokinetic properties, and they complied with Lipinski's rule of 5 indicating that they are predicted to be orally bioavailable, and they possess a predicted bioavailability score of 0.55. Furthermore, in SwissADME Boiled-Egg chart, all compounds showed high predicted GIT absorption, and while compounds 6a-g showed blood brain barrier (BBB) permeation, the compounds 8a-g did not. Moreover, all compounds are not p-glycoprotein (P-gp) substrates.